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Abstract
Background: Simpson's paradox is sometimes referred to in the areas of epidemiology and clinical
research. It can also be found in meta-analysis of randomized clinical trials. However, though
readers are able to recalculate examples from hypothetical as well as real data, they may have
problems to easily figure where it emerges from.
Method: First, two kinds of plots are proposed to illustrate the phenomenon graphically, a scatter
plot and a line graph. Subsequently, these can be overlaid, resulting in a overlay plot. The plots are
applied to the recent large meta-analysis of adverse effects of rosiglitazone on myocardial infarction
and to an example from the literature. A large set of meta-analyses is screened for further
examples.
Results: As noted earlier by others, occurrence of Simpson's paradox in the meta-analytic setting,
if present, is associated with imbalance of treatment arm size. This is well illustrated by the
proposed plots. The rosiglitazone meta-analysis shows an effect reversion if all trials are pooled. In
a sample of 157 meta-analyses, nine showed an effect reversion after pooling, though non-significant
in all cases.
Conclusion: The plots give insight on how the imbalance of trial arm size works as a confounder,
thus producing Simpson's paradox. Readers can see why meta-analytic methods must be used and
what is wrong with simple pooling.
Background
Simpson's paradox, also known as the ecological effect,
was first described by Yule in 1903 [1] and is named after
Simpson's article in 1951 [2]. It refers to the phenomenon
that sometimes an association between two dichotomous
variables is similar within subgroups of a population, say
females and males, but changes its sign if the individuals
of the subgroups are pooled without stratification. This is
reflected in the title of a paper by Baker and Kramer
('Good for women, good for men, bad for people', [3]).
There are numerous examples, particularly from the areas
of epidemiology and social sciences, of associations
strongly affected by observed or unobserved dichotomous
variables [4-8]. Even a tale based on Simpson's paradox
has been told [9]. The reason for its occurrence is the exist-
ence of an influencing variable that is not accounted for,
often unobserved. Thus, it may seem that the effect is char-
actistic for observational studies and can be avoided by
randomization.
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This is not true, as was pointed out by others [10-14]. As
Altman and Deeks note, Simpson's paradox is not really a
paradoxon, but a form of bias, resulting from heterogene-
ity in the data if not accounted for [10]. Often tables of
hypothetical as well as real data examples are presented.
However, though these examples are easily recalculated,
there is a need for readers, especially clinicians and practi-
tioners in other fields, to really understand the nature of
the phenomenon.
Baker and Kramer proposed a plot, later called the Baker-
Kramer (BK) plot, which was independently invented by
others much earlier, for graphically illustrating Simpson's
paradoxon [3,13-15]. Their examples stem from hypo-
thetical data. For this plot it is required that the influenc-
ing variable is dichotomous. In the setting of a meta-
analysis, however, the main source of heterogeneity and
thus the most important influential variable is well-
known and not dichotomous in general: it is the variable
'trial'. A perfect example of Simpson's paradox occurring
in a meta-analysis of case-control studies is given by
Hanley and Theriault [8]. In this meta-analysis all single
trials show an increased risk for exposed individuals,
while the pooled analysis reverses this effect.
As a (less perfect) example for meta-analysis of RCTs, we
use a recent systematic review of the effect of rosiglitazone
on the risk of myocardial infarction and death from cardi-
ovascular diseases [16]. It stated a significant increase of
myocardial infarctions in the rosiglitazone group. The
authors found a Peto odds ratio 1.428 with 95 per cent
confidence interval [1.031; 1.979] and p-value 0.0321
(fixed effect model) [17]. This meta-analysis immediately
raised a discussion not only about the safety of the drug,
but also on methodological issues referring to potential
heterogeneity, different follow-up times, the large number
of trials with no or very few events and the imbalanced
group sizes within many trials [18-20]. A re-analysis of the
data using several variants of the Mantel-Haenszel
method found that the significance of the effect is ques-
tionable (odds ratio estimates between 1.26 and 1.36,
most of them not significant) [18]. Though not consist-
ently significant, meta-analysis (all methods) exhibits an
excess of events in the treatment group (rosiglitazone),
compared to the control group (any other regimen). For
example, taking the risk difference (fixed effect model,
Mantel-Haenszel method) results in a combined estimate
of 0.002 (95 per cent confidence interval [0.000; 0.004]
with p-value 0.0549), corresponding to an estimated
NNH (Number Needed to Harm) of about 489 patients.
One problem of this data is the large number of trials
without any events. If the outcome is measured by the risk
ratio or the odds ratio, these trials are often excluded from
a meta-analysis because it is argued that they do not con-
tribute any information about the magnitude of the treat-
ment effect [21]. In order to use all available information,
simple pooling of all single tables could be rather tempt-
ing. It is seemingly convenient here because of the consid-
erable number of double-zero studies, despite of the
general consensus that this is discouraged [22]. If pooling
is done – in spite of this objection – for the main endpoint
myocardial infarction (MI), we in fact surprisingly observe
that the pooled 2 × 2-table provides the contrary: the risk
of MI for the treated individuals is 0.0055 and therefore
less than for the control group (0.0059), see Table 1. The
pooled odds ratio is 0.94 with 95 per cent confidence
interval [0.69; 1.29] (p-value 0.7109). This (non-signifi-
cant) effect reversion, produced by pooling, was observed
by another author who in the light of these found the
results of the meta-analysis 'intriguing' [23]. It can be seen
as a milder form of Simpson's paradox.
In the next section, we first develop two kinds of plots to
reveal and illustrate the mechanism of Simpson's paradox
and effect reversion, using the rosiglitazone example. The
third plot emerges from overlaying both plots. In the
results section, we apply the plots to the data given by
Hanley and Theriault [8] and discuss both methods and
results. The paper is ended with conclusions.
Methods and Results
Simpson's paradox for continuous variables
The first idea to give a pictorial representation of the data
is very simple. It comes from a graphic that serves for dem-
onstrating the continuous version of the effect. For exam-
ple, think of a correlation study where the data are
grouped by a nominal variable Z, say study center. The
conditional correlation (i.e. the correlation, given Z) of
two continuous variables X, Y is assumed to be positive
for all values of Z. Simpson's paradox occurs if, on the
other hand, between different levels of Z holds 'the higher
X, the lower is Y '. The appropriate plot best illustrating
this is given by Figure 1. It is a grouped scatterplot that
shows approximately parallel ascending regression lines
within each level of Z, but a decreasing sequence of mid-
points. Our goal is now to transfer this idea to the case of
both X and Y being dichotomous.
Table 1: Pooled data of rosiglitazone meta-analysis (full data see 
ref. [16])
Events Total Fraction
Rosiglitazone group 86 15556 0.5528%
Control group 72 12277 0.5865%BMC Medical Research Methodology 2008, 8:34 http://www.biomedcentral.com/1471-2288/8/34
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Simpson's paradox for dichotomous variables: a 
scatterplot
Let X, Y be dichotomous variables, where X is the treat-
ment (1 = active, 0 = control) and Y is the outcome of
interest (e.g., 1 = MI, 0 = no MI, where MI means myocar-
dial infarction). The grouping variable is denoted as Z. In
our meta-analytic example, Z ∈ {1,..., N} is the trial (N =
42 for the rosiglitazone meta-analysis). Simpson's para-
dox occurs, e.g., if within (most) studies, the event Y is
more frequent in the active treatment group (X = 1), but
between studies, those with larger treatment proportions
(corresponding to higher X) tend to exhibit lower event
probabilities (corresponding to lower Y). This is possible
only if the proportions of patients treated with the active
drug vary substantially over all trials. Exactly this – the
noticeable imbalance of the groups in many of the studies
– is a characteristic feature of the rosiglitazone meta-anal-
ysis, as is pointed out both in the original article [16] and
several reactions thereon, e.g. [18]. The connection
between group imbalance and the occurrence of ecologi-
cal effects was pointed out earlier by some authors
[8,10,11].
Figure 2 (left panel) is a straightforward analogue to the
continuous plot described above. Instead of the (dichoto-
mous) variables X and Y themselves, their observed fre-
quencies are used. A simple scatterplot is presented that
shows the overall event frequencies P(Y = 1|Z = i) within
the N trials i = 1,..., N versus the proportions P(X = 1|Z =
i) of patients undergoing the active treatment. The large
dispersion of the treatment proportions, unusual for ran-
domized trials, is clearly seen. The negative correlation
between treatment proportion and event probability
(indicated by the fitted unweighted regression line) could
lead to the deceptive impression that the frequency of
adverse events decreases if more patients receive active
treatment, thus potentially producing Simpson's paradox.
Simpson's paradox for dichotomous variables: a line plot
A second way to demonstrate this is given by Figure 2
(middle panel). It shows, according to the scatterplot for
continuous variables, the actual treatment X (i.e, 0 or 1)
on the x-axis and the event frequencies conditional on
group (X = 0 or X = 1) and trial (Z), that is P(Y = 1|X, Z)
on the y-axis. Points belonging to the same trial are joined
by a thin line, so that different lines indicate different tri-
Scatterplot of correlation between two continuous variables X and Y, grouped by a nominal variable Z Figure 1
Scatterplot of correlation between two continuous variables X and Y, grouped by a nominal variable Z. Different 
colors represent different levels of Z.
0 1
0
1
X
YBMC Medical Research Methodology 2008, 8:34 http://www.biomedcentral.com/1471-2288/8/34
Page 4 of 8
(page number not for citation purposes)
als. The slope of each within-trial line corresponds to the
risk difference of this trial. The lines show a tendency to
increase for most trials, revealing more adverse events in
the active treatment group, in agreement with the pub-
lished result of the meta-analysis.
In addition, three other lines are drawn. The green line
joins the estimated mean event frequencies under control
and under rosiglitazone, calculated within trials and aver-
aged with equal weights for all trials. The blue line is sim-
ilar, but the trials are now weighted with their precision,
measured by the inverse sampling variance, calculated
from a meta-analysis using the risk difference as outcome
measure. Both lines increase slightly, reflecting what in
average happens within trials.
The red line, however, calculated by simple collapsing all
2 × 2-tables without stratification by trial, decreases. The
reason is that there are many unbalanced trials with the
treatment groups being larger than the control groups and
simultaneously having the lowest event rates (see Figure
2, left panel). We can visualize this by adding further ele-
ments to this plot. The starting and ending points of the
single trial lines are marked by diamonds with size pro-
portional to the size of the control group and the treat-
ment group of this trial, respectively. If this is done, the
contribution of single trial arms to the red line becomes
visible. In our example, we have a large trial with many
events in the control group (left) and, on the other hand,
many trials with a larger proportion of rosiglitazone
patients having low event rates (right-hand side).
Three plots elucidating effect reversion in rosiglitazone meta-analysis: (a) Scatterplot of fraction of events against proportion of  patients in the active treatment group (left panel) Figure 2
Three plots elucidating effect reversion in rosiglitazone meta-analysis: (a) Scatterplot of fraction of events 
against proportion of patients in the active treatment group (left panel). (b) Line plot displaying risk differences 
within trials (middle panel). 0 = control group, 1 = active treatment group. (c) Overlay plot of scatterplot and line plot (right 
panel).
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Simpson's paradox for dichotomous variables: the overlay 
plot
The right panel plot of Figure 2 shows a combination of
the scatterplot and the line plot. The circles from the scat-
terplot and the trial-specific lines from the line plot are
overlaid, while the regression line, the colored lines and
the diamonds are skipped for sake of clarity. The interpre-
tation of the x-axis and the lines now is slightly changed.
Values x on the x-axis are interpreted as all possible pro-
portions of active treatment in a trial. The y-values on the
line belonging to a particular trial indicate the expected
frequency of events in this trial, given X = x. If X = 0, this
corresponds to the observed fraction of events in the con-
trol group (the intercept). If X = 1, the value provides the
observed fraction of events in the treatment group of the
trial. The i'th line is thus given by the linear equation
y = PZ = i(Y = 1|X = 0) + [PZ = i(Y = 1|X = 1) - PZ = i(Y = 1|X 
= 0)] x,( 1 )
where the slope PZ = i(Y = 1|X = 1) - PZ = i(Y = 1|X = 0) is
the risk difference observed in trial Z = i, as stated above.
If we insert for x the proportion x0 of patients actually
treated in trial i, that is x0 = PZ = i(X = 1), we get
y0 = PZ = i(Y = 1|X = 0) + [PZ = i(Y = 1|X = 1) - PZ = i(Y = 1|X 
= 0)] PZ = i(X = 1),
which results (after straightforward simplification) in y0 =
PZ = i(Y = 1), the overall frequency of events in trial i. These
values are marked as the circles on the lines in the right-
hand panel, which are the same as those on the scatterplot
(left panel). This equality corresponds to equation (1) in
[4].
Application
We apply the plots to the example of meta-analysis of
case-control studies given by Hanley and Theriault (data
in reference [8]). The cases are children with leukemia, the
exposition of interest being the presence of a high voltage
power line within 100 m of the residence. Figure 3 dis-
plays the plots for this example. The y-axes are logit-trans-
formed, because effect is measured as odds ratio. The
scatterplot (left-hand panel) shows that the proportion of
exposed (children living near a power line, here expressed
as log odds) was higher in studies with a lower case-con-
trol ratio. The line plot (middle panel) displays that
within all studies the exposition is slightly associated with
leukemia, likewise for the stratified meta-analysis (green
and blue line), but in the pooled sample (red line) the
direction of association is reversed. The diamonds dis-
close how the large case and control groups pull the red
line in the opposite direction. A direct overlay of these
plots would not make sense, because when using a non-
linear transformation of the y-axis, the circles of the scat-
terplot do not lie exactly on the lines of the line plot.
Instead, by subjecting equation (1) to the logit transfor-
mation we get a curved counterpart to the overlay plot.
This is shown in the right-hand panel of Figure 3.
Discussion
The example of the rosiglitazone meta-analysis illustrates
that an ecological effect can occur even if all studies are
randomized clinical trials. The scatterplot, applied to this
example, shows that the myocardial infarction rate is the
lower, the higher the proportion of patients in the active
treatment groups is. This is no effect of the treatment, but
an artefact of the studies included in this meta-analysis.
The large majority of treated patients in some trials is
explained by the fact that the authors pooled multiple
groups of patients receiving rosiglitazone, where applica-
ble [16]. On the other hand, many of these studies had
only short-time follow-up, so that there were only few
events observed. Casually, we note that this kind of heter-
ogeneity in study design is present although there was no
indication of statistical heterogeneity of the treatment
effect on any scale, as measured in terms of τ2, H or I2[24].
These measures do not capture heterogeneity in other
respect. This taken into account, the result of the meta-
analysis that more adverse events are attributed to treat-
ment than to control, as claimed to be significant in [16],
was questioned by others [18].
In general, even a strong correlation contrary to the
within-study association does not necessarily cause an
effect reversion. This happens only if the disparities of the
treatment arm sizes are large enough to outbalance the
treatment effect in the single trials. This can be judged by
inspection of the line plot. The line plot displays the treat-
ment effect in each single study, as the slope of each line
corresponds to the treatment effect measured in this
study. The slope of the green line is the (uniformly
weighted) mean treatment effect, that of the blue line the
weighted mean treatment effect, the latter corresponding
to the result of a meta-analysis. This kind of plot is not
restricted to the risk difference, as the second example
shows. Rather, it is easily generalized to a plot for the risk
ratio or the odds ratio or other measures of treatment
effect, such as the arcsine difference [25], by using the log
scale, the logit scale, or the arcsine scale for the y-axis,
respectively.
If the y-axis is not transformed, the plots can be overlaid.
At first glance, the overlay plot is evocative of the so-called
BK-plot [3,13-15]. It was first demonstrated using a hypo-
thetical situation with only two groups (males and
females), with the female fraction of patients as x-axis and
the two lines corresponding to the two treatments [3]. The
BK-plot was applied, for example, to medical school
admission data [26]. There is, however, a fundamentalBMC Medical Research Methodology 2008, 8:34 http://www.biomedcentral.com/1471-2288/8/34
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difference between our overlay plot and the BK-plot
which is elucidated in Table 2. In the overlay plot, the x-
axis represents the variable 'treatment', that is, propor-
tions of patients treated with the active treatment, and the
lines correspond to any number of strata (here trials). In
the BK-plot, however, x represents a binary confounder
(i.e., proportions of patients belonging to one of two sub-
groups), and the lines correspond to the treatments. In
fact, the BK-plot was originally introduced to elucidate
Simpson's paradox for the simplest case that both the
treatment variable and the confounding variable are
binary. The plot then contains only two lines and two cir-
cles. Insight comes from comparing the position of the
two circles on these lines: If Simpson's paradox is work-
ing, the lines have the same direction, do not intersect,
and the circle on the lower line lies higher than the circle
on the upper line. This method of pairwise comparing cir-
cles does not work in the context of a large and maybe het-
erogeneous meta-analysis. The confounder, here the trial,
is not binary. Moreover, Simpson's paradox in meta-anal-
ysis uses to occur in a generalized form: We do not presup-
pose that the effects within all studies have the same
direction. An effect reversion is identified if the sign of the
pooled effect differs from that of the within-study treat-
ment effect, estimated using meta-analytic methods.
As mentioned before, looking at the scatterplot or the
overlay plot alone does not suffice, because a strong asso-
ciation between the proportion of patients treated and the
event frequency in the direction opposite to the treatment
effect is not sufficient for an effect reversion. The essential
Three plots illustrating Simpson's paradox in a meta-analysis of case-control studies: (a) Scatterplot of frequency of exposition  (on a log odds scale) against proportion of cases (left panel) Figure 3
Three plots illustrating Simpson's paradox in a meta-analysis of case-control studies: (a) Scatterplot of fre-
quency of exposition (on a log odds scale) against proportion of cases (left panel). (b) Line plot displaying log odds 
ratios within studies (middle panel). 0 = control group, 1 = case group. (c) Curved overlay plot (right panel).
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information is given by the line plot or by using the whole
triplet of plots.
In addition, we screened a large set meta-analyses for find-
ing further examples of this phenomenon. This data set,
consisting of 157 meta-analyses with binary endpoints
and two treatment groups was kindly provided by Peter
Jüni who had collected the data at the Department of
Social and Preventive Medicine, University of Berne, Swit-
zerland. We had formerly used these data for a study on
publication bias [27]. For each meta-analysis, a 'Simpson
check' is carried out by comparing the sign of the result of
the pooled analysis to the sign of the meta-analytic result,
using the risk difference (without loss of generality). We
found that in 9 out of all 157 meta-analyses (5.7%) the
sign changed. However, in all these examples the treat-
ment effect was far from being significant, and the confi-
dence intervals of the meta-analytic and the pooled
estimate overlapped largely. Hence the change of the sign
was of no statistical importance.
Conclusion
The rosiglitazone example illustrates that an ecological
effect (Simpson's paradox) can occur even when all stud-
ies are randomized clinical trials. However, as our empir-
ical study shows, this is not a common phenomenon.
When it occurs, it is caused by strong imbalance of the
proportions allocated to the active and control treatment
in the trials included in the meta-analysis. The usual
measures of heterogeneity on the treatment effect scale are
not sensitive against this kind of heterogeneity.
In our opinion, the plots proposed here serve to clarify
what is going on beyond the calculations. Taken together,
they help the reader to understand what is behind Simp-
son's paradox if he faces it in a meta-analysis. The R code
producing the plots is available from the first author on
request [28].
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